The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > REGULATORY
REGULATORY
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
- LDP Study Group Calls for Postponing Off-Year Re-Pricing
June 9, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- JPMA Urges Govt to Establish “Headquarters” for Infectious Disease Control Policy: Chief
June 9, 2020
- MHLW Grants Orphan Status to 8 APIs
June 8, 2020
- Minister Mentions First Half 2021 Goal for Coronavirus Vaccination Start
June 8, 2020
- ASEAN + 3 Ministers Vow to Work towards Smooth Drug Distribution amid COVID-19
June 8, 2020
- Saliva-Based COVID-19 PCR Tests Reimbursed for Cases within 9 Days of First Symptoms: MHLW
June 4, 2020
- Japan Eyes Coronavirus Vaccination Launch in First Half of 2021
June 3, 2020
- Label Updates Ordered for Uptravi, Plavix, Permitting Their Concomitant Use: MHLW
June 3, 2020
- Japan OKs Add’l Indications for Ofev, Xtandi/Erleada and More
June 1, 2020
- Oral Semaglutide Clears MHLW Panel, Now in Line for June Approval
June 1, 2020
- MHLW Panel Gives Blessing to 1st Triple Combo Therapy for Asthma; Humira Biosimilar Also in Line for June OK
May 29, 2020
- Japan Sets 30 Day Prescription Limit for Shionogi’s ADHD Med Vyvanse
May 29, 2020
- 145.5 Billion Yen Allocated for COVID-19 Vaccine Production in Second Extra Budget: MHLW
May 29, 2020
- GSK’s Cost-Effectiveness Analysis for Trelegy Delayed, First Product under Full CEA Scheme
May 28, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Council to Discuss Medical Needs for Additional Indications for Antiemetics Ondansetron, Granisetron
May 27, 2020
- Japan’s First Humalog Biosimilar to Join NHI Price List on May 27
May 26, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…